ZYLM (Central Asia Lumeichun Biotechnology) LT-Debt-to-Total-Asset: 0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Central Asia Lumeichun Biotechnology LT-Debt-to-Total-Asset?

Central Asia Lumeichun Biotechnology ZYLM LT-Debt-to-Total-Asset is 0.00 as of Jun. 2026.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Central Asia Lumeichun Biotechnology's long-term debt to total assests ratio for the quarter that ended in Jun. 2026 was 0.00.

Central Asia Lumeichun Biotechnology's long-term debt to total assets ratio stayed the same from Jun. 2025 (0.00) to Jun. 2026 (0.00).

Central Asia Lumeichun Biotechnology  (OTCPK:ZYLM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Central Asia Lumeichun Biotechnology LT-Debt-to-Total-Asset Related Terms

Central Asia Lumeichun Biotechnology LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Central Asia Lumeichun Biotechnology's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Central Asia Lumeichun Biotechnology LT-Debt-to-Total-Asset Chart

Central Asia Lumeichun Biotechnology Annual Data
Trend Mar07 Mar08 Mar09 Mar10 Mar11 Mar14 Mar15 Aug23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Central Asia Lumeichun Biotechnology Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun13 Jun15 Sep15 Dec15 Nov22 Feb23 May23 Aug23 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Central Asia Lumeichun Biotechnology LT-Debt-to-Total-Asset Calculation

Central Asia Lumeichun Biotechnology's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0.021535/3.25762
=0.01

Central Asia Lumeichun Biotechnology's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2026 is calculated as

LT Debt to Total Assets (Q: Jun. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2026 )/Total Assets (Q: Jun. 2026 )
=0.01055/4.725224
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Central Asia Lumeichun Biotechnology (ZYLM) has a LT-Debt-to-Total-Asset of 0.00 as of Jun. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Central Asia Lumeichun Biotechnology and its competitors.
Is Central Asia Lumeichun Biotechnology's LT-Debt-to-Total-Asset too high?
Central Asia Lumeichun Biotechnology's current LT-Debt-to-Total-Asset is 0.00.
How does Central Asia Lumeichun Biotechnology's LT-Debt-to-Total-Asset compare to RHE and DVCR?
Central Asia Lumeichun Biotechnology's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Consumer Packaged Goods company?
A good LT-Debt-to-Total-Asset depends on the Consumer Packaged Goods industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Central Asia Lumeichun Biotechnology and its competitors. Central Asia Lumeichun Biotechnology's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Asia Lumeichun Biotechnology stock overvalued right now?
Central Asia Lumeichun Biotechnology (ZYLM) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Central Asia Lumeichun Biotechnology (ZYLM), the current LT-Debt-to-Total-Asset is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Central Asia Lumeichun Biotechnology Business Description

Address Longguan Avenue, Room 1401, Yunhua Building, Longhua District, Shenzhen, CHN
Central Asia Lumeichun Biotechnology Inc is an ecological agriculture company. It operates a sika deer breeding base in southern China.